# Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

> **NCT06106308** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cardiff Oncology** · enrollment: 113 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- CRC
- KRAS/NRAS Mutation

## Interventions

- **DRUG:** Onvansertib
- **DRUG:** FOLFIRI
- **DRUG:** Bevacizumab
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT06106308
- **Lead sponsor:** Cardiff Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-27
- **Primary completion:** 2026-11
- **Final completion:** 2027-01
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106308, "Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06106308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*